EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efgartigimod in generalized myasthenia gravis: A real‐life experience at a national reference center

Rita Frangiamore, Elena Rinaldi, Fiammetta Vanoli, Francesca Andreetta, Emilio Ciusani, Silvia Bonanno, Lorenzo Maggi iD, Annamaria Gallone, Anna Colasuonno, Irene Tramacere, Marta Cheli, Alessandro Pinna und 2 weitere

European Journal of Neurology · 2024-04 · 31 (4)

DOI: 10.1111/ene.16189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 02.01.2024. Verfasst von Rita Frangiamore und 13 weiteren Autor:innen. Beteiligte Einrichtung: Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy. Hauptthemen laut MEDLINE: Activities of Daily Living, Myasthenia Gravis. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Inhibition of the neonatal Fc receptor (FcRn) for IgG is a promising new therapeutic strategy for antibody‐mediated disorders. We report our real‐life experience with efgartigimod (EFG) in 19 patients with generalized myasthenia gravis (gMG) along a clinical follow‐up of 14 months.

Methods

EFG was administered according to the GENERATIVE protocol (consisting of a Fixed period of two treatment cycles [given 1 month apart] of four infusions at weekly intervals, followed by a Flexible period of re‐cycling in case of worsening). Eight patients were positive for acetylcholine receptor antibody, four for muscle‐specific tyrosine kinase antibody, and two for lipoprotein‐related protein 4 antibody, and five were classified as triple negative. Efficacy of EFG was assessed by the Myasthenia Gravis Activities of Daily Living, Myasthenia Gravis Composite, and Quantitative Myasthenia Gravis scales.

Results

Fifty‐three percent of patients needed three treatment cycles, 26% needed four, and 21% needed five along the 14‐month clinical follow‐up. Meaningful improvement was observed at the end of each cycle with the clinical scores adopted. EFG had a dramatic effect on disease course, as during the year before treatment eight of 19 patients (42%) were hospitalized, and 15 of 19 (79%) needed treatment with plasma exchange or immunoglobulins; three of 19 (16%) were admitted to the intensive care unit. During EFG, none of the patients was hospitalized and only one patient required plasma exchange and intravenous immunoglobulins. No major side effects or infusion‐related reactions occurred.

Conclusions

We observed that EFG was safe and modified significantly the course of the disease along a 14‐month follow‐up. Our experience strengthens the role of FcRn inhibition as an effective new tool for long‐term treatment of gMG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Activities of Daily LivingMyasthenia GravisInfant, NewbornHumansAutoantibodiesPlasma Exchange

Stichwörter der Autor:innen

MuSKacetylcholine receptorefgartigimodmyasthenia gravisneonatal Fc receptor

Substanzen

Autoantibodies

Autor:innen und Institutionen

  • Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.
  • Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
  • Laboratory of Neurological Biochemistry and Neuropharmacology, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.
  • Department of Research and Clinical Development, Scientific Directorate, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.
  • argenx Italy, Milan, Italy.
  • Immunotherapy and Apheresis Departmental Unit, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.

ORCID-Profile: Lorenzo Maggi, Renato Mantegazza, Carlo Antozzi

Zitieren

APA

Frangiamore, R., Rinaldi, E., Vanoli, F., Andreetta, F., Ciusani, E., Bonanno, S., Maggi, L., Gallone, A., Colasuonno, A., Tramacere, I., Cheli, M., Pinna, A., Mantegazza, R., & Antozzi, C. (2024). Efgartigimod in generalized myasthenia gravis: A real‐life experience at a national reference center. European Journal of Neurology, 31(4). https://doi.org/10.1111/ene.16189

Vancouver

Frangiamore R, Rinaldi E, Vanoli F, Andreetta F, Ciusani E, Bonanno S, et al. Efgartigimod in generalized myasthenia gravis: A real‐life experience at a national reference center. European Journal of Neurology. 2024;31(4). doi:10.1111/ene.16189

BibTeX
@article{Frangiamore2024,
  author = {Frangiamore, Rita and Rinaldi, Elena and Vanoli, Fiammetta and Andreetta, Francesca and Ciusani, Emilio and Bonanno, Silvia and Maggi, Lorenzo and Gallone, Annamaria and Colasuonno, Anna and Tramacere, Irene and Cheli, Marta and Pinna, Alessandro and Mantegazza, Renato and Antozzi, Carlo},
  title = {Efgartigimod in generalized myasthenia gravis: A real‐life experience at a national reference center},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {4},
  doi = {10.1111/ene.16189}
}
Kostenlos starten →